- Positive FDA discussions for Actimab-MDS program enable accelerated pivotal trial pathway and broaden target patient population
- Actimab-A development strategy in combinations with Venetoclax for AML informed by company research indicating potential synergy and support from leading physicians
PR Newswire
NEW YORK, Oct. 30, 2018